Menogaril

Menogaril
Names
	Other names 7-O-Methylnogarol
Identifiers
CAS Number	71628-96-1 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL1234391 ;
ChemSpider	4450900 ;
PubChem CID	5288818;
UNII	8JSV4O30HQ ;
	InChI InChI=1S/C28H31NO10/c1-27(36)8-10-6-11-16(21(32)15(10)14(9-27)37-5)22(33)17-13(30)7-12-24(18(17)20(11)31)38-26-23(34)19(29(3)4)25(35)28(12,2)39-26/h6-7,14,19,23,25-26,30,32,34-36H,8-9H2,1-5H3/t14-,19+,23+,25-,26-,27-,28-/m1/s1 Key: LWYJUZBXGAFFLP-OCNCTQISSA-N ; InChI=1/C28H31NO10/c1-27(36)8-10-6-11-16(21(32)15(10)14(9-27)37-5)22(33)17-13(30)7-12-24(18(17)20(11)31)38-26-23(34)19(29(3)4)25(35)28(12,2)39-26/h6-7,14,19,23,25-26,30,32,34-36H,8-9H2,1-5H3/t14-,19+,23+,25-,26-,27-,28-/m1/s1 Key: LWYJUZBXGAFFLP-OCNCTQISBR;
	SMILES C[C@@]1(C[C@H](C2=C(C3=C(C=C2C1)C(=O)C4=C5C(=CC(=C4C3=O)O)[C@@]6([C@@H]([C@H]([C@@H]([C@H](O5)O6)O)N(C)C)O)C)O)OC)O;
Properties
Chemical formula	C28H31NO10
Molar mass	541.55 g/mol
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	verify (what is ?)
	Infobox references

Menogaril is an anthracycline analog of nogalamycin which was developed in late 1970s. It has even stronger anticancer activity than nogalamycin and has less toxicity than nogalamycin. However, its development for clinical use was cancelled due to only moderate success with relatively high incidence of serious toxicity (43-44% in non-Hodgkin's lymphoma patients).[1]

References

Moore DF Jr; Brown TD; LeBlanc M; Dahlberg S; Miller TP; McClure S; Fisher RI. (1999). "Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial". Invest New Drugs. 17 (2): 169–72. doi:10.1023/A:1006375301205.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Moore_1999-1] Moore DF Jr; Brown TD; LeBlanc M; Dahlberg S; Miller TP; McClure S; Fisher RI. (1999). "Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial". Invest New Drugs. 17 (2): 169–72. doi:10.1023/A:1006375301205.